In Silico simulation of long-term type 1 diabetes glycemic control treatment outcomes

Journal of Diabetes Science and Technology

Volumn 2, Issue 3, 2008, Pages 436-449

  Wong, Xing Wei ^a   Chase, J Geoffrey ^a   Hann, Christopher E ^a   Lotz, Thomas F ^a   Lin, Jessica ^a   Le Compte, Aaron J ^a   Shaw, Geoffrey M ^b  

^a UNIVERSITY OF CANTERBURY   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Blood glucose; Compartmental models; Decision support; Diabetes; Hyperglycemia; Insulin; Simulation; Subcutaneous injection

Indexed keywords

EID: 80051592581     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680800200313     Document Type: Conference Paper

References (54)

1. Bequette BW. A critical assessment of algorithms and challenges in the development of a closed-loop artificial pancreas. Diabetes Technol Ther. 2005;7(1):28-47.
2. Bellazzi R, Nucci G, Cobelli C. The subcutaneous route to insulin-dependent diabetes therapy. IEEE Eng Med Biol Mag. 2001;20(1):54-64.
3. Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes. 2006;55(12):3344-50.
4. Steil GM, Panteleon AE, Rebrin K. Closed-loop insulin deliverythe path to physiological glucose control. Adv Drug Deliv Rev. 2004;56(2):125-44.
5. Klonoff DC, Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care. 2005;28(5):1231-9.
6. Guidance on the use of continuous subcutaneous insulin infusion for diabetes. Technology Appraisal Guidance No. 57, National Institute for Clinical Excellence; 2003. Available from: www.nice.org.uk.
7. Position statement on insulin pump therapy. Position statement on insulin pump therapy, Diabetes UK [cited 2007 Aug. 8]. Available from: www.diabetes.org.uk.
8. ADA. Standards of medical care in diabetes-2006. Diabetes Care. 2006;29; S4-S42.
9. Mainous AG 3rd, Diaz VA, Saxena S, Baker R, Everett CJ, Koopman RJ, Majeed A. Diabetes management in the USA and England: comparative analysis of national surveys. J R Soc Med. 2006;99(9):463-9.
10. Cohen M, Boyle E, Delaney C, Shaw J. A comparison of blood glucose meters in Australia. Diabetes Res Clin Pract. 2006;71(2):113-8.
11. Guerci B, Floriot M, Böhme P, Durain D, Benichou M, Jellimann S, Drouin P. Clinical performance of CGMS in type 1 diabetic patients treated by continuous subcutaneous insulin infusion using insulin analogs. Diabetes Care. 2003;26(3):582-9.
12. Gerich JE. Novel insulins: expanding options in diabetes management. Am J Med. 2002;113(4):308-16.
13. Wong J, Chase JG, Hann CE, Lotz TF, Lin J, Le Compte A, Shaw GM. Development of a clinical type 1 diabetes metabolic system model and in silico simulation tool. J Diabetes Sci Technol. 2008;2(3):423-435.
14. Reed K, Lehmann ED. Diabetes website review: www.2aida.org. Diabetes Technol Ther. 2005;7(5):741-54.
15. Guerci B, Sauvanet JP. Subcutaneous insulin: pharmacokinetic variability and glycemic variability. Diabetes Metab. 2005;31(4 Pt 2):4S7-4S24.
16. Stephens E, Riddle M. Evolving approaches to intensive insulin therapy in type 1 diabetes: multiple daily injections, insulin pumps and new methods of monitoring. Rev Endocr Metab Disord. 2003;4(4):325-34.
17. Gallen IW, Carter C. Prospective audit of the introduction of insulin glargine (lantus) into clinical practice in type 1 diabetic patients. Diabetes Care. 2003;26(12):3352-3.
18. Distiller LA, Joffe BI. From the coalface: does glargine insulin improve hypoglycaemic episodes, glycaemic control or affect body mass in type 1 diabetic subjects who are attending a 'routine' diabetes clinic? Diabetologia. 2006;49(11):2793-4.
19. Anderson JH Jr, Brunelle RL, Koivisto VA, Pfützner A, Trautmann ME, Vignati L, Di Marchi R. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes. 1997;46(2):265-70.
20. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000;23(5):644-9.
21. Sämann A, Mühlhauser I, Bender R, Kloos Ch, Müller UA. Glycaemic control and severe hypoglycaemia following training in flexible, intensive insulin therapy to enable dietary freedom in people with type 1 diabetes: a prospective implementation study. Diabetologia. 2005;48(10):1965-70.
22. Wong J, Chase JG, Hann CE, Shaw GM, Lotz TF, Lin J, Le Compte AJ. A subcutaneous insulin pharmacokinetic model for computer simulation in a diabetes decision support role: model structure and parameter identification. J Diabetes Sci Technol. In press 2008.
23. Wong J, Chase JG, Hann CE, Shaw GM, Lotz TF, Lin J, Le Compte AJ. A subcutaneous insulin pharmacokinetic model for computer simulation in a diabetes decision support role: validation and simulation. J Diabetes Sci Technol. In press 2008.
24. Bruttomesso D, Pianta A, Crazzolara D, Capparotto C, Dainese E, Zurlo C, Minicuci N, Briani G, Tiengo A. Teaching and training programme on carbohydrate counting in Type 1 diabetic patients. Diabetes Nutr Metab. 2001;14(5):259-67.
25. Warshaw HS, Kulkarni K. Complete guide to carb counting: how to take the mystery out of carb counting and unlock the secrets to blood glucose control. 2nd ed. Virginia: American Diabetes Association; 2004.
26. Gregory RP, Davis DL. Use of carbohydrate counting for meal planning in type I diabetes. Diabetes Educ. 1994;20(5):406-9.
27. Kildegaard J, Randløv J, Poulsen JU, Hejlesen OK. The impact of non-model-related variability on blood glucose prediction. Diabetes Technol Ther. 2007;9(4):363-71.
28. Lehmann ED, Deutsch T. AIDA2: A Mk. II automated insulin dosage advisor. J Biomed Eng. 1993;15(3):201-11.
29. BD Diabetes Learning Centre. Insulin therapies. Managing diabetes with insulin. 2006. Available from: http://www.bddiabetes.com/us/main.aspx?cat= 1&id=151.
30. Walsh J, Roberts R. The pocket pancreas: your diabetes guide for improved blood sugars. Diabetes Services Inc.; 1994.
31. Hanas R. Type 1 diabetes - a guide for children, adolescents, young adults and their caregivers. New York: Marlowe & Company; 2005.
32. Dalla Man C, Caumo A, Basu R, Rizza R, Toffolo G, Cobelli C. Minimal model estimation of glucose absorption and insulin sensitivity from oral test: validation with a tracer method. Am J Physiol Endocrinol Metab. 2004;287(4):E637-43.
33. Korach-André M, Roth H, Barnoud D, Péan M, Péronnet F, Leverve X. Glucose appearance in the peripheral circulation and liver glucose output in men after a large 13C starch meal. Am J Clin Nutr. 2004;80(4):881-6.
34. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care. 1999;22(5):801-5.
35. Woodworth J, Howey D, Bowsher R, Lutz S, Santa P, Brady P. [Lys (B28), Pro (B29)] human insulin (K)-dose-ranging vs humulin R (H). Diabetes. 1993;42:A54.
36. Fritsche A, Schweitzer MA, Häring HU; 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med. 2003;138(12):952-9.
37. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080-6.
38. De Witt DE, Dugdale DC. Using new insulin strategies in the outpatient treatment of diabetes: clinical applications. JAMA. 2003;289(17):2265-9.
39. Holman RR, Turner RC. A practical guide to basal and prandial insulin therapy. Diabet Med. 1985;2(1):45-53.
40. Sanofi-Aventis, LANTUS (insulin glargine [rDNA origin] injection). Prescribing information [cited 2007 Oct. 11]. Available from: http://products.sanofi-aventis.us/lantus/lantus.html>
41. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2002;48(3):436-72.
42. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA (1c): analysis of glucose profiles and HbA (1c) in the Diabetes Control and Complications Trial. Diabetes Care. 2002;25(2):275-8.
43. Lehmann ED. Simulating glycosylated hemoglobin (HbA1c) levels in diabetes using an interactive educational virtual diabetes patient simulator. Diabetes Technol Ther. 2001;3(3):517-24.
44. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-86.
45. AACE. Medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management-2002 update. Endocr Prac. 2002;8(Suppl. 1):40-64.
46. Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care. 1998;21(11):1904-9.
47. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005;28(5):1245-9.
48. Heller SR, Macdonald IA, Herbert M, Tattersall RB. Influence of sympathetic nervous system on hypoglycaemic warning symptoms. Lancet. 1987;2(8555):359-63.
49. Mitrakou A, Ryan C, Veneman T, Mokan M, Jenssen T, Kiss I, Durrant J, Cryer P, Gerich J. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol. 1991;260(1 Pt 1):E67-74.
50. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26(6):1902-12.
51. Blonde L, Karter AJ. Current evidence regarding the value of self-monitored blood glucose testing. Am J Med. 2005;118(Suppl 9A):20S-26S.
52. Monnier L, Colette C, Lapinski H, Boniface H. Self-monitoring of blood glucose in diabetic patients: from the least common denominator to the greatest common multiple. Diabetes Metab. 2004;30(2):113-9.
53. Davidson PC, Hebblewhite HR, Bode BW, Steed RD, Steffes PG. Statistically fitted curve for A1c as a function of the SMBG tests per day. Presented at 64th Scientific Sessions of the American Diabetes Association, Orlando, Florida; 2004.
54. Morris AD, Boyle DI, McMahon AD, Greene SA, MacDonald TM, Newton RW. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside Scotland. Medicines Monitoring Unit. Lancet. 1997;350(9090):1505-10.